Premium
P2‐003: Clinical Trial Design of Cread: A Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Phase 3 Study to Evaluate Crenezumab Treatment in Patients with Prodromal‐To‐Mild Alzheimer’s Disease
Author(s) -
Blaettler Thomas,
Smith Janice,
Smith Jillian,
Paul Robert,
Asnaghi Veronica,
Fuji Reina,
Quartino Angelica,
Honigberg Lee,
Rabbia Michael A.,
Yule Susan,
Ostrowitzki Susanne,
Fontoura Paulo
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.1207
Subject(s) - placebo , medicine , clinical endpoint , asymptomatic , clinical trial , double blind , phases of clinical research , randomized controlled trial , disease , gastroenterology , pathology , alternative medicine
with sustained suppression at all doses. After multiple doses, change from baseline in mean CSF Ab42 was 63.2 and 79.3% in the 15 and 50 mg AZD3293 groups, respectively, with similar reductions in Ab40 (Table 2). Baseline CSFAb42 levels were similar in the healthy Japanese and non-Japanese subjects. Conclusions: AZD3293 was generally well tolerated and potently reduced plasma and CSFAb peptides in Japanese adult subjects. Reductions in CSF Ab peptides were similar to those previously reported in non-Japanese subjects with AD.